Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Intestinal Malabsorption

In brief

To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.

Key facts

Study ID

NCT05904626

Run by

Elgan Pharma Ltd.

People needed

60

Starts

2025-10-28

Expected to finish

2027-06-01

Last updated by the study team

2026-04-09

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female preterm infant born less than 26 weeks GA or Intra-Uterine Growth Restricted infants born between 26+0 to 31+6 GA.
• Birth weight ≥ 450g
• Singleton or twin birth

You may not qualify if…

• N/A

Where it is running

• Laniado Hospital — Netanya, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.